0001209191-21-001380.txt : 20210105 0001209191-21-001380.hdr.sgml : 20210105 20210105173812 ACCESSION NUMBER: 0001209191-21-001380 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210105 DATE AS OF CHANGE: 20210105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: YOUNG JAMES F CENTRAL INDEX KEY: 0001219864 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-26770 FILM NUMBER: 21507417 MAIL ADDRESS: STREET 1: ONE MEDIMMUNE WAY CITY: GAITHERSBURG STATE: MD ZIP: 20878 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NOVAVAX INC CENTRAL INDEX KEY: 0001000694 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 222816046 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 21 FIRSTFIELD ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 240-268-2000 MAIL ADDRESS: STREET 1: 21 FIRSTFIELD ROAD CITY: GAITHERSBURG STATE: MD ZIP: 20878 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-31 0 0001000694 NOVAVAX INC NVAX 0001219864 YOUNG JAMES F C/O NOVAVAX, INC. 21 FIRSTFIELD ROAD GAITHERSBURG MD 20878 1 0 0 0 Common Stock 2020-12-31 4 M 0 1000 50.00 A 1000 D Common Stock 2020-12-31 4 M 0 10000 51.40 A 11000 D Common Stock 2020-12-31 4 S 0 9000 112.9805 D 2000 D Common Stock 2020-12-31 4 S 0 2000 113.595 D 0 D Common Stock 2021-01-01 4 M 0 10000 A 10000 D Common Stock 1500 I By spouse Stock Option (Right to Buy) 50.00 2020-12-31 4 M 0 1000 0.00 D 2011-09-10 2021-03-10 Common Stock 1000 0 D Stock Option (Right to Buy) 51.40 2020-12-31 4 M 0 10000 0.00 D 2011-10-19 2021-04-19 Common Stock 10000 0 D Restricted Stock Units 2021-01-01 4 M 0 10000 0.00 D Common Stock 10000 10000 D The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.45 to $113.43, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.47 to $113.78, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Fifty percent (50%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on January 1, 2021, and the remaining fifty percent (50%) of the RSUs subject to this grant will vest on July 1, 2021, in each case subject to continued service on the Company's Board of Directors through the vesting date. /s/ John A. Herrmann III, Attorney-in-Fact 2021-01-05